The article offers guidelines on how to administer Tissue Plasminogen Activator (TPA) to an adult suffering from acute ischemic stroke in the U.S. It states that patient and family must be informed about the intracere...
doi:10.1038/ncpcardio0426BraybrookClaireNature Clinical Practice Cardiovascular Medicine
The use of tissue plasminogen activator (tPA) is the major treatment method for acute ischemic stroke, but it reaches only a very limited number of stroke patients. Although neuroprotectants may be useful in stroke patients in principle, promising animal data have not yet been successfully transfer...
TREATMENT OF ACUTE ISCHEMIC STROKE OR INTRACRANIAL BLEEDING WITH TPA AND CARBAMYLATED ERYTHROPOIETINThe present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tPa and a therapeutically effective amount of carbamylated ...
Despite the fact that more than 100 agents have been tested in the treatment of ischemic stroke, none, with the exception of tPA, has proven effective. Most Recent Failure The most recent failure was the investigational drug NXY-059 (Cerovive, AstraZeneca). In late October, AstraZeneca announ...
To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant mor...
Median National Institutes of Health Stroke Scale (NIHSS) was 10.8 pretreatment, 3 at 24 hours, and 2.1 on hospital discharge. IV tPA treatment rate increased from 4.7% to 10.3% between 1999 and 2003. Conclusion: IV tPA for acute ischemic stroke can be given safely and effectively by ...
Ischemic stroke is a common neurological disease. Currently, there are no Food and Drug Administration-approved drugs that can maximize the improvement in
Bryan D. Hayes, PharmD, FAACT, FASHP, is an assistant professor of emergency medicine and clinical pharmacist at Harvard Medical School/Massachusetts General Hospital. He is also an associate editor and the creator of the CAPSULES series ofAcademic Life in Emergency Medicine (ALiEM). His resear...
However, tPA has a narrow therapeutic window of only 4.5 h from the onset of symptom [5]. Consequently, most stroke patients don't qualify for this treatment and would greatly benefit from the development of novel treatments that have an expanded therapeutic window [5]. Adult stem cell-based...